These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31149783)

  • 1. Investigation of screening method for DNMT3A mutations by high-resolution melting analysis in acute myeloid leukemia.
    Mizuta S; Yamane N; Komai T; Koba Y; Kawata T; Ukyo N; Tamekane A; Watanabe M
    Int J Lab Hematol; 2019 Oct; 41(5):593-600. PubMed ID: 31149783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
    El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations.
    Kumar D; Mehta A; Panigrahi MK; Nath S; Saikia KK
    Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):82-89. PubMed ID: 29079128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of NPM1 exon 12 mutations and FLT3 - internal tandem duplications by high resolution melting analysis in normal karyotype acute myeloid leukemia.
    Tan AY; Westerman DA; Carney DA; Seymour JF; Juneja S; Dobrovic A
    J Hematol Oncol; 2008 Jul; 1():10. PubMed ID: 18664261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.
    Loghavi S; Zuo Z; Ravandi F; Kantarjian HM; Bueso-Ramos C; Zhang L; Singh RR; Patel KP; Medeiros LJ; Stingo F; Routbort M; Cortes J; Luthra R; Khoury JD
    J Hematol Oncol; 2014 Oct; 7():74. PubMed ID: 25281355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients.
    Gorniak P; Ejduk A; Borg K; Makuch-Lasica H; Nowak G; Lech-Maranda E; Prochorec-Sobieszek M; Warzocha K; Juszczynski P
    Eur J Haematol; 2016 Feb; 96(2):181-7. PubMed ID: 25891904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
    Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features and prognostic significance of DNMT3A, FLT3, and NPM1 mutations in de novo acute myeloid leukemia patients.
    Chen M; Zeng Z; Li X; Qin W; Cai X; Chen S; Lu X
    Int J Lab Hematol; 2023 Dec; 45(6):899-907. PubMed ID: 37519024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia.
    Wakita S; Marumo A; Morita K; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Ueki T; Uoshima N; Kobayashi Y; Kawata E; Nakayama K; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Hagihara M; Uchiyama H; Uchida N; Kubota Y; Kimura S; Nagoshi H; Ichinohe T; Kurosawa S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Tashiro H; Sakaguchi M; Yui S; Arai K; Kitano T; Miyata M; Arai H; Kanda M; Itabashi K; Fukuda T; Kanda Y; Yamaguchi H
    Cancer Sci; 2023 Apr; 114(4):1297-1308. PubMed ID: 36610002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis.
    Singh RR; Bains A; Patel KP; Rahimi H; Barkoh BA; Paladugu A; Bisrat T; Ravandi-Kashani F; Cortes JE; Kantarjian HM; Medeiros LJ; Luthra R
    J Mol Diagn; 2012 Jul; 14(4):336-45. PubMed ID: 22642896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model.
    Poitras JL; Heiser D; Li L; Nguyen B; Nagai K; Duffield AS; Gamper C; Small D
    Oncotarget; 2016 Oct; 7(43):69124-69135. PubMed ID: 27636998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNMT3A co-mutation is required for FLT3-ITD as an adverse prognostic indicator in intermediate-risk cytogenetic group AML.
    Ma J; Dunlap J; Paliga A; Traer E; Press R; Shen L; Fan G
    Leuk Lymphoma; 2018 Aug; 59(8):1938-1948. PubMed ID: 29165010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
    Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
    Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
    Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
    Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
    Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C
    Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia.
    Meyer SE; Qin T; Muench DE; Masuda K; Venkatasubramanian M; Orr E; Suarez L; Gore SD; Delwel R; Paietta E; Tallman MS; Fernandez H; Melnick A; Le Beau MM; Kogan S; Salomonis N; Figueroa ME; Grimes HL
    Cancer Discov; 2016 May; 6(5):501-15. PubMed ID: 27016502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis.
    Kao HW; Liang DC; Kuo MC; Wu JH; Dunn P; Wang PN; Lin TL; Shih YS; Liang ST; Lin TH; Lai CY; Lin CH; Shih LY
    Oncotarget; 2015 Oct; 6(32):33217-25. PubMed ID: 26375248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia.
    Berenstein R; Blau IW; Kar A; Cay R; Sindram A; Seide C; Blau O
    J Exp Clin Cancer Res; 2014 May; 33(1):44. PubMed ID: 24887327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia.
    Wakita S; Yamaguchi H; Omori I; Terada K; Ueda T; Manabe E; Kurosawa S; Iida S; Ibaraki T; Sato Y; Todoroki T; Hirakawa T; Ryotokuji T; Arai K; Kitano T; Mitamura Y; Kosaka F; Dan K; Inokuchi K
    Leukemia; 2013 Apr; 27(5):1044-52. PubMed ID: 23135354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association.
    Renneville A; Boissel N; Nibourel O; Berthon C; Helevaut N; Gardin C; Cayuela JM; Hayette S; Reman O; Contentin N; Bordessoule D; Pautas C; Botton Sd; Revel Td; Terre C; Fenaux P; Thomas X; Castaigne S; Dombret H; Preudhomme C
    Leukemia; 2012 Jun; 26(6):1247-54. PubMed ID: 22289988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.